Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aprepitant

FDA-approved product (capsule, oral), marketed as Aponvie, Aprepitant, Cinvanti and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Aprepitant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiemetics
FDA pharmacologic class
Substance P/Neurokinin-1 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aprepitant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aprepitant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

    NCT03578081 · start 2018-11-20

    Registered record
    Registry ID
    NCT03578081
    Conditions
    Malignant Neoplasm
    Interventions
    Palonosetron Hydrochloride; Ondansetron Hydrochloride; Dexamethasone; Fosaprepitant Dimeglumine; Olanzapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-20
    Completion
    2023-05-01
    Enrolment
    690

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    InterventionPalonosetron Hydrochloride; Ondansetron Hydrochloride; Dexamethasone; Fosaprepitant Dimeglumine +2 more
    PhasePhase 3
    Registry statusCompleted

  • Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

    NCT02939287 · start 2017-09-23

    Registered record
    Registry ID
    NCT02939287
    Conditions
    Nausea; Vomiting
    Interventions
    o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1; Olanzapine10 mg orally daily on Days -1,0,+1 and +2; Aprepitant plus Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-23
    Completion
    2022-12-01
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting
    Interventiono Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1; Olanzapine10 mg orally daily on Days -1,0,+1 and +2; Aprepitant plus Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

    NCT03245918 · start 2017-08-10

    Registered record
    Registry ID
    NCT03245918
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Aprepitant Capsule 125 MG; Aprepitant oral suspension 20 mg/mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-10
    Completion
    2018-01-05
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionAprepitant Capsule 125 MG; Aprepitant oral suspension 20 mg/mL
    PhasePhase 1
    Registry statusCompleted

  • Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

    NCT02625181 · start 2016-07

    Registered record
    Registry ID
    NCT02625181
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Automated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery; Anesthesia Information Management System (AIMS); Perioperative Data Warehouse (PDW); General anesthesia; Elective surgery; Propofol; Sevoflurane; Isoflurane; Desflurane; Scopolamine; Droperidol; Haloperidol; Dexamethasone; Promethazine; Meclizine; Aprepitant; Metoclopramide; Fentanyl; Sufentanil; Alfentanil; Remifentanil; Morphine; Meperidine; Hydromorphone; Methadone; Oxycodone; Oxymorphone; Hydrocodone; Ketamine; Ondansetron; Granisetron; Dolasetron mesylate; Palonosetron; Tropisetron; Ramosetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-11-30
    Enrolment
    27,034

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionAutomated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery +34 more
    PhaseNot applicable
    Registry statusCompleted

  • Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

    NCT02646020 · start 2015-12

    Registered record
    Registry ID
    NCT02646020
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Aprepitant; Desloratadine; Placebo of aprepitant; Placebo of desloratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-12
    Completion
    2020-12-01
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAprepitant; Desloratadine; Placebo of aprepitant; Placebo of desloratadine
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

    NCT02519842 · start 2015-09-14

    Registered record
    Registry ID
    NCT02519842
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Fosaprepitant; Placebo for fosaprepitant; Ondansetron; Dexamethasone; 5-HT3 antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-09-14
    Completion
    2017-02-24
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionFosaprepitant; Placebo for fosaprepitant; Ondansetron; Dexamethasone +1 more
    PhasePhase 3
    Registry statusTerminated

  • Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

    NCT02484911 · start 2015-05

    Registered record
    Registry ID
    NCT02484911
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Olanzapine; Aprepitant; Palonosetron; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionOlanzapine; Aprepitant; Palonosetron; Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis

    NCT02336750 · start 2014-12

    Registered record
    Registry ID
    NCT02336750
    Conditions
    Breast Cancer
    Interventions
    Aprepitant; Mirtazapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2021-12
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAprepitant; Mirtazapine
    PhasePhase 3
    Registry statusCompleted

  • Developing Individualized Strategies to Prevent Nausea and Vomiting

    NCT01393288 · start 2013-11

    Registered record
    Registry ID
    NCT01393288
    Conditions
    Postoperative Nausea and Vomiting; Genetic Polymorphisms
    Interventions
    Ondansetron; Lorazepam; Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2013-11
    Completion
    2015-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting; Genetic Polymorphisms
    InterventionOndansetron; Lorazepam; Aprepitant
    PhaseNot applicable
    Registry statusWithdrawn

  • Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

    NCT01697579 · start 2012-12-13

    Registered record
    Registry ID
    NCT01697579
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Fosaprepitant; Fosaprepitant Placebo; Ondansetron; 5-hydroxytryptamine 3 antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12-13
    Completion
    2016-11-21
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionFosaprepitant; Fosaprepitant Placebo; Ondansetron; 5-hydroxytryptamine 3 antagonist
    PhasePhase 2
    Registry statusCompleted

  • Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

    NCT01625455 · start 2012-02

    Registered record
    Registry ID
    NCT01625455
    Conditions
    Sezary Syndrome; Pruritus
    Interventions
    Aprepitant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2016-07
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSezary Syndrome; Pruritus
    InterventionAprepitant; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

    NCT01523457 · start 2011-10

    Registered record
    Registry ID
    NCT01523457
    Conditions
    Metastatic Pancreatic Cancer; Pancreatic Cancer
    Interventions
    Folfirinox
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-10
    Completion
    2015-12
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Cancer; Pancreatic Cancer
    InterventionFolfirinox
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Adding EMEND to PONV/PDNV Treatment Regimen

    NCT01186029 · start 2011-09-01

    Registered record
    Registry ID
    NCT01186029
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2011-09-01
    Completion
    2011-09-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    Interventionaprepitant
    PhaseNot applicable
    Registry statusWithdrawn

  • Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone

    NCT01536691 · start 2011-06

    Registered record
    Registry ID
    NCT01536691
    Conditions
    Cancer; Malignancy
    Interventions
    ramosetron; ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-06
    Completion
    2013-02
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Malignancy
    Interventionramosetron; ondansetron
    PhasePhase 3
    Registry statusUnknown

  • Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

    NCT01298193 · start 2011-05

    Registered record
    Registry ID
    NCT01298193
    Conditions
    Breast Cancer
    Interventions
    Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2014-04
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAprepitant
    PhasePhase 4
    Registry statusCompleted